Drug Development Consultant & Regulatory Consultant

How to Write a Business Plan

how-to-write-a-business-plan-100%-programme

How to Write a Business Plan

Turn your Project into an Investment Magnet – £300 (we are in Beta) free E-course

Pharmaceutical and Biotechnology projects need a business plan if they are going to raise finance, and that is just what we are here to help you achieve. We are going to assist you in putting together a business plan that will ensure that your healthcare technology project gets the funding it needs. We will turn your project into an investment magnet. Good business plans raise money and you are going to be very please you took our advice, sign up now for our course.

Over the years IDA consultants have worked with a large number of companies to undertake the planning process and provide the contents they need for their business plan, and 100% of our clients obtained the funding they needed to take them to the next step.

£300 (we are in Beta Free) E-course on How to Write a Business Plan

Our £300 (we are in Beta) Free E-course on how to write a business plan will take you through an 11 step programme and provides an outline of the sections of the business plan, guidance on the kind of information that is needed and useful resource and document templates. Fill in the Form to Join and Turn Your Business into an Investor Magnet.

Sign up for £300 Free (we are in Beta)

We don’t like spam, we will not share your data and we will guard it like you would.

First name

Last name

Company name

Street address

Zip or postal code

Country

E-mail address

Course Content

  • Session 1 – Situation Review; before you can decide where your going, its important to understand where you are now.
  • Session 2 – Indication Review; what is your target indication? what other opportunities are there? its all about adding value.
  • Session 3 – Intellectual Property; this is where your value lies, its critical to protect and optimize it, its not just about patents.
  • Session 4 – Regulatory Strategy; the regulations are the gatekeepers to the market and the correct strategy can be the difference between success and failure. You will be a success.
  • Session 5 – Markets; its not market sizes its market dynamics, investors know this, do you?
  • Session 6 – Indication Selection; make sure your going for the correct markets to optimize your goals and strategies.
  • Session 7 – Development planning; how are you going to develop this product? quickly and cost effectively? its risk management.
  • Session 8 – Manufacturing and GMP; knowing how the requirements will impact on your business is critical to cash flow and strategy.
  • Session 9 – Regulatory Advice, get your plans rubber stamped, it adds masses of credibility, a real investor magnet.
  • Session 10 – Cost and Financial Planning; you know what your going to do, but just how much is it going to cost?
  • Session 11 – The Business Plan; bringing it all together to attract the investment.

The Book

This course is extracted from the definitive book on How to Write a Business Plan for Health Technology Companies. We will make this book avaialble to you shortley, its just undergoing its final edit and will soon be printed.

Take advantage of our 100% fundraising record when writing your business plan.

Trackbacks & Pingbacks

  1. Drug Regulations, EMEA publishes ICH E16 - Genomic Biomarkers for Drug Responses | Drug Development Consultant and Regulatory Consultant pingbacked Posted July 30, 2009, 4:18 pm
  2. Drug Regulators - Traditional Herbal Medicines Advertising Guidance | Drug Development Consultant and Regulatory Consultant pingbacked Posted July 31, 2009, 8:13 am
  3. Increased Biotech Market Protection – USA | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 3, 2009, 8:39 am
  4. Drug Regulators, FDA New Draft Guidance | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 4, 2009, 9:21 am
  5. Drug Regulations, MHRA draft guidance on ATMP under the hospital exemption scheme. | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 5, 2009, 9:13 am
  6. Clinical Trials Regulations, EU Commission, Clinical Trials Draft Regulations | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 6, 2009, 12:11 pm
  7. Genomic Medicine, House of Lords Science and Technology Committee Publishes Report | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 7, 2009, 8:54 am
  8. Clinical Trial Regulations - FDA publishes FAQ on IRB registration | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 10, 2009, 8:32 am
  9. Post Markeing Clinical Trials Planning - Imprelentation of the FDA section 505(o) - Draft Guidance | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 11, 2009, 9:14 am
  10. Drug Development Guidance - FDA publish impurities guidance for ANDAs | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 12, 2009, 10:34 am
  11. Drug Development Guidance - FDA Guidance on Postmarketing Adverse Event Reporting | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 13, 2009, 9:34 am
  12. Drug Development Guidance - EMEA for Medical Products for Term and Preterm Neonates | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 17, 2009, 8:29 am
  13. Drug Development Guidance - FDA publish Drug Induced Livery Injust Evaluation Guidance | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 19, 2009, 2:06 pm
  14. Drug Regulators Publish ICH consideration on Virus and Vector Shredding | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 21, 2009, 8:02 am
  15. Draft Guidance Published by Drug Regulators on CE-marked Medical Devices - Neurostimulators | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 24, 2009, 8:02 am
  16. Drug Regulators Publish Concept Paper on Clinical Investigations of Specific Immunoglobulins | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 25, 2009, 11:17 am
  17. Drug Regulators International Collaberation on GCP Inspections | Drug Development Consultant and Regulatory Consultant pingbacked Posted August 27, 2009, 10:45 am
  18. Drug Regulators Publish Concept Paper on CJD and Plasma-Derived Medicinal Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 8, 2009, 10:23 am
  19. Drug Regulatos, FDA, Reppost Guidance on CMC Submissions for Therapeutic Recombinant DNA-Derived Products or Monolconal Antibody Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 14, 2009, 9:08 am
  20. Drug Regulators publish Guidance on Risk for Melamine Contamination | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 28, 2009, 9:04 am
  21. Drug Regulators Publish Draft Guidance on E16 Genomic Biomarkers Related to Drug Response | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 28, 2009, 9:09 am
  22. Drug Regulators Publish Guidance on the Investigation of Medicincal Products in the Term and Preterm Neonate | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 28, 2009, 9:14 am
  23. Drug Regulators Publish Concept Paper on Paediatirc Pulmonary Arterial Hypertension | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 28, 2009, 9:20 am
  24. Drug Regulators Publish Concept Paper Requiremtns for Guidance on the Clinical Investigation of Products for Lipid Disorders and Hypertension | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 28, 2009, 9:25 am
  25. Regulators Publish Q&A's on EWP therapeutic subgroups on Pharmacokinetics | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 29, 2009, 2:43 pm
  26. Drug Regulators Publish Draft Guidance on Clinical Investigations for Factor VIII Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 29, 2009, 2:47 pm
  27. Drug Regulators Publish Draft Guidance on Clinical Investigations for Factor IX Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 29, 2009, 2:50 pm
  28. Drug Regulators Publish Guidance on Clinical Evaluation of Diagnostic Agents | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 29, 2009, 2:57 pm
  29. Drug Regulators Publish Concept Paper on Clinical Investigation of Specific Immunoglobulins | Drug Development Consultant and Regulatory Consultant pingbacked Posted September 29, 2009, 3:01 pm
  30. Device Regulators Publish Guidance on Vigilance System for CE marked Breast Implants | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 12, 2009, 1:52 pm
  31. Drug Regulators Publish Draft Guidnace on Consumer Advertising of Traditional Herbal Medicines | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 12, 2009, 1:56 pm
  32. Drug Regulators Publishes Guidance on Managing Donor Risk for HIV-1 | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 12, 2009, 2:01 pm
  33. Drug Regulators Publish Guidnace for Formal Meetings | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 16, 2009, 2:50 pm
  34. METRC Announce Short Term Project Funding | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 16, 2009, 3:55 pm
  35. Pan African Registry is Given WHO Thumbs Up | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 16, 2009, 4:14 pm
  36. The Human Fertilisation and Embryology Act Comes into Force | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 16, 2009, 4:17 pm
  37. European Medicines Agency implements internal reorganisation | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 16, 2009, 4:21 pm
  38. Drug Regualtors Publish Intnetion to Change Regualtiosn on Sale, Supply and Administration of Drus and Dental Hygenists and Dental Therapists | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 17, 2009, 3:00 pm
  39. Drug Regulators Publish Guidance on Tacrolimus Development | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 18, 2009, 3:00 pm
  40. Parallel Scientific Advice at the Regualtors | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 19, 2009, 3:08 pm
  41. Drug Regulators Publish Draft Guidance on Development of Similar Recombinant Erythroproetins Containing Prodcuts | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 20, 2009, 3:12 pm
  42. Drug Regulators Publish Q&A on ICH M2 - Common Technical Document for the Registration of Pharmaceuticals for Human Use | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 21, 2009, 3:18 pm
  43. Drug Regulator Publishes Core SPC for Pandemic Influenza Vaccines | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 22, 2009, 3:23 pm
  44. Drug Regulators Publish Draft Clinical Guidelines for Cancer Vaccines | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 26, 2009, 10:59 am
  45. Drug Regulators Publish Draft Guidance on Biosimilars for Recombinant Erthropoietins | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 27, 2009, 11:05 am
  46. Drug Regulators Publish Guidance on End-of-Phase 2a Meetings | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 28, 2009, 11:09 am
  47. Drug Regulators Publish Draft Guidance on Development, Analysis and Presentaion of Microbological Data for Systemic Antibarterial Drugs | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 29, 2009, 11:10 am
  48. Drug Regulators Publish Guidance for Allogenic Pancreatic Islet Cell Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 30, 2009, 11:24 am
  49. FDA Publishes New Guidance Page - Memoranda to Blood Establishments | Drug Development Consultant and Regulatory Consultant pingbacked Posted October 31, 2009, 12:17 pm
  50. Drug Regulators Publish Guidance Notice on Borderlines with Medical Devices | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 2, 2009, 5:40 pm
  51. Drug Regulatos Publish Draft Reflection Paper on In-vitro Cultured Chondrocyte Containing Products for Cartilage Repair | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 3, 2009, 5:44 pm
  52. Regulators Publish Draft Guidance for industry on Risk Evaluation and Mitigation Strategies (REMS) | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 4, 2009, 5:54 pm
  53. The purpose of this guidance is to assist sponsors in clinical drug development for the treatment of adults with duodenal ulcers caused byHelicobacter pylori (H. pylori) for the reduction of duodenal ulcer recurrence. Specifically, this guidance addresses pingbacked Posted November 5, 2009, 9:20 pm
  54. EU Directive updated, - Advanced Therapy Medical Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 6, 2009, 9:32 pm
  55. Drug Regulators EMEA publish Draft Guidance on the Use of Near Infrared Spectroscopy | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 10, 2009, 3:44 pm
  56. Drug Regulators Publish Concept Paper on the Need to Revise Clinical Guidance for Depression | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 11, 2009, 4:00 pm
  57. Drug Regulators, FDA, Publish a Good Review Practice Guidance for Labeling for Human Prescription Drug and Biological Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 12, 2009, 4:07 pm
  58. FDA Publishes Guidance on Circular Information for the Use of Human Blood and Blood Components | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 13, 2009, 4:06 pm
  59. Drug Regulators, FDA, Publish Draft Guidance on IND's for Minimally Manipulated, Unrelated Allogenic Placental/Umbilical Cord Blood | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 14, 2009, 4:12 pm
  60. Drug Regulators, FDA, Publish Guidance for Minimally Manipulated, Unrelated Allogenic Placental/Umbilical Cord Blood Intended for Hematopoiteic Reconstitution for Specific Indications | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 16, 2009, 4:31 pm
  61. Medical Device Regulators Publish Guidance on Vigilance Systems Breast Implants | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 19, 2009, 12:05 pm
  62. Drug Regulators, EMEA, Re-Publish Guidance on Special Populations Geriatrics | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 20, 2009, 12:19 pm
  63. Liver Toxicity, FDA DILI Regulations Require Interpretation | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 20, 2009, 5:15 pm
  64. Drug Regulator, EMEA, Publishes ICH Guidance on the use of Oncolytic Viruses | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 21, 2009, 12:31 pm
  65. European Commission Publishes Assessment of the Functioning of the Clinical Trials Directive | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 22, 2009, 12:37 pm
  66. Drug Regulators, FDA (CDER), Publishes Guidance on SPL Standard for Content of Labeling Technical Qs & As | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 23, 2009, 12:49 pm
  67. Drug Regulators, FDA CDER, Publish Updated Guidance on Investigator Responsibilities for Study Subjects | Drug Development Consultant and Regulatory Consultant pingbacked Posted November 24, 2009, 5:19 pm
  68. Drug Regulators, EMEA, Publish Concept Paper on Revision of Guidelines on Radiopharmaceuticals Based on Monoclonal Antibodies | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 2, 2009, 11:05 am
  69. Drug Regulators, FDA, Publish Guidance on Nucleic Acid Tests to Reduce Risk of West Nile Virus from Whole Blood Donors | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 5, 2009, 11:24 am
  70. MHRA puts new Traditional Herbal Medicines Registration Scheme Page Live | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 8, 2009, 8:19 am
  71. MHRA Re-Publish Guidance On How they Regulate Traditional Herbal Medicines (THMRS) | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 9, 2009, 8:23 am
  72. EMEA Publishes Draft Guidance on the Development of Medical Products for Insomnia | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 11, 2009, 8:52 am
  73. Medical Device Classification not Centrally Stored | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 11, 2009, 10:15 am
  74. FDA Convenes Meeting Regarding Online Advertising | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 12, 2009, 9:01 am
  75. EMEA Publishes Comments Received on Development of Guidance for Products for Treating Smoking | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 13, 2009, 9:01 am
  76. FDA Publishes Draft Guidance on E7 Studies in Support of Special Populations: Geriatrics Q&A | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 16, 2009, 11:20 am
  77. Drug Regulators, EMEA, CHMP Publish Guidance on Follow-up Patients Adminstered with Gene Therapy Medical Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 16, 2009, 11:25 am
  78. Department Of Health Announce an Innovation Pass Pilot | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 22, 2009, 9:04 am
  79. Drug Regulators, EMEA, Publish Reflection Paper on the Extrapolation of Results from Clinical Studies Conducted Outside the EU | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 23, 2009, 8:24 am
  80. Good Publication Practice for Communicating Company Sponsored Medical Research; the GPP2 Guidelines Published | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 23, 2009, 9:06 am
  81. Drug Regulators, FDA, Publish Q4B Evaluation and Recomendations for Pharmacopeial Texts for use in ICH regions, Annex 11: Capillary Electrophoresis General Chapter | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 23, 2009, 10:40 am
  82. Drug Regulators, FDA, Publish Draft Guidance on Manufactures of Human Cells,Tissues and Cellular and Tissue Based Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 24, 2009, 8:30 am
  83. Drug Regulator, EMEA, Publishes New Visual Identity, web/email addresses and organisation chart for the European Medicines Agency | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 24, 2009, 9:25 am
  84. Drug Regulators, FDA, Publish Q4B Evaluation and Recommendations for Pharmacopeial Texts for use in ICH regions, Annex 12: Analytical Sieving General Chapter | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 24, 2009, 10:43 am
  85. Drug Regulators Publish, ICH Q4B, Annex 7 Dissolution Test General Chapter Guidance | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 24, 2009, 11:00 am
  86. Drug Regulators, FDA, Publishes Guidance on Pharmaceutical Development Q8(R2) | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 25, 2009, 8:29 am
  87. Drug Regulators, FDA, CDER, Publish Draft Guidance on Assay Development for Immunogenicity Testing of Therapeutic Proteins | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 25, 2009, 9:45 am
  88. Drug Regulators, FDA, Publish Addendum to ICH S6: preclinical safety evaluation of biotechnology-derived pharmaceuticals S6(R1) | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 25, 2009, 10:47 am
  89. Drug Regulators Publish, ICH M2, Business Requirements Guidance | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 25, 2009, 11:02 am
  90. Drug Regulators, FDA, Publish Questions and Answers on GMP, and Production, Process, Control | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 26, 2009, 8:32 am
  91. Drug Regulators, EMEA, Publish Concept Paper on the Need for Clinical Guidelines for the Investigation of Medicinal Products for the Treatment of Systemic and Cutaneous Lupus Erythematosus | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 26, 2009, 9:53 am
  92. Drug Regulators, EMEA, Publish ICH S9 Guidance, Nonclinical Evaluation for Anticancer Pharmaceuticals | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 26, 2009, 10:27 am
  93. Drug Regulators, EMEA, Publish ICH M2, Common Technical Document, Updated Q&A | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 26, 2009, 11:05 am
  94. Drug Regulators, EMEA, Publish Concept Paper on the Development of a Guidance on Similar Biological Medicinal Products Containing Monoclonal Antibodies | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 27, 2009, 8:39 am
  95. Drug Regulators, FDA, CDER, Publish Guidance on Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 29, 2009, 10:27 am
  96. Drug Regulators, EMEA, Publish Guidline on Xenogenic Cell-Based Medicinal Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 31, 2009, 8:58 am
  97. Drug Regulators, EMEA, Publish ICH Q4B, Annex 10, Polyacrylamide Gel Electrophoresis General Chapter Guidance | Drug Development Consultant and Regulatory Consultant pingbacked Posted December 31, 2009, 10:57 am
  98. Drug Regulator, MHRA, Starts Consultation on Measures to Strengthen the Medicines Supply Chain and Reduce the Risk of Counterfit Medicines | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 5, 2010, 8:26 am
  99. Drug Regulator, MHRA, Publishes an Updated Guide for Manufactures on Clinical Investigations to be Carried out in the UK | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 6, 2010, 8:29 am
  100. Drug Regulators, FDA CDER, Publish Guidance on Q4B Annex5 Disintegration Test General Chapter for ICH regions | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 7, 2010, 8:33 am
  101. Drug Regulators, FDA CDER, Publish Guidance on Q4B Annex 8 Sterility Test General Chapter for ICH Regions | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 8, 2010, 8:41 am
  102. Drug Regulators, FDA, Publish Guidance on An Acceptable Circular of Information for the Use of Human Blood and Blood Components | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 9, 2010, 8:41 am
  103. Drug Regulators, FDA, Publish Guidance for Industry on New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products. | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 11, 2010, 9:07 am
  104. Drug Regulatory Guidance, Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products. | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 12, 2010, 9:13 am
  105. Drug Regulators, EMEA, Publish Questions and Answers on Gene Therapy | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 18, 2010, 9:43 am
  106. Drug Regulators, European Medicines Agency, Publish Concept Paper on Revision of the Notes for Guidance on Gene Transfer Medicinal Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 19, 2010, 9:49 am
  107. Drug Regulators, EMEA, Publish Guidance on the Evaluation of Drugs for the Treatment of Gastroesophageal Reflux Disease | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 20, 2010, 9:54 am
  108. Device Regulators, MHRA, Publish Poster on Mattress Decontamination | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 21, 2010, 9:57 am
  109. £70 million Boost for UK manufacturing (including Regenerative medicines) | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 22, 2010, 10:04 am
  110. Drug Regulators, EMEA, Publish Guidance on Herbal Medicinal Products, Test Materials for Genotoxicity | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 25, 2010, 10:18 am
  111. Regulators Publish Guidance for Industry, Non Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization. | Drug Development Consultant and Regulatory Consultant pingbacked Posted January 26, 2010, 10:13 am
  112. Dedication Recognised – IDA wins award for mentor work | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 1, 2010, 12:44 pm
  113. Drug Regulators, EMEA, Publish Draft Concept Paper on the Risk Based Approach for Advanced Therapy Medical Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 1, 2010, 4:36 pm
  114. Drug Regulators EMEA, Publish Guidance on Clinical Investigations of Medicinal Products Intended for the Treatment of Glucocorticoid-Induced Osteoporosis | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 3, 2010, 4:51 pm
  115. Drug Regulators, EMEA, Publish Guideline on Investigations of Medicinal Products in the Treatment of Epileptic Disorders | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 4, 2010, 4:49 pm
  116. Drug Regulators, EMEA, Release Overview of Comments Received on Draft Guidance on Clinical Evaluation of Diagnostic Agents. | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 5, 2010, 4:54 pm
  117. Drug Regulators, FDA - CDER, Publish Guidance on Use of Mechanical Calibration of Dissolution Apparatus CGMP | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 6, 2010, 4:55 pm
  118. Drug Regulators, FDA- CDER, Publish Guidance on the Assessment of Abuse Potential of Drugs. | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 7, 2010, 5:00 pm
  119. Drug Regulators, EMA, Publish Overview of Comments Received on Reflection Paper, Ethanol Content in Herbal Medicinal Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 8, 2010, 12:19 pm
  120. Drug Regulators, EMA, Publish Reflection Paper on Ethanol Content in Herbal Medicinal Products and Tranditional Herbal Medicinal Products Used in Children | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 9, 2010, 12:27 pm
  121. Drug Regulators EMEA, Publish Overview of Comments Received on Selection of Test Materials for Genotoxicity Testing For Traditional Herbal Medicinal Products | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 11, 2010, 11:41 am
  122. Drug Regulators, MHRA, Publish Consultation, Intention to Amend the Medicines for Human Use Regulations 2008 (SI2008/1692) | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 12, 2010, 11:42 am
  123. Drug Regulators, MHRA, Publish Consultation Letter MLX 364, The Regulation of Nicotine Containing Products. | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 13, 2010, 11:48 am
  124. Drug Regulators, EMEA, Publish Concept Paper on Need to Revise Points to Consider on the Clinical Investigation of Medicinal Products Other than NSAIDs in Rheumatoid Arthritis | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 14, 2010, 11:58 am
  125. Drug Regulators, EMEA, Publish an Overview of Comments Received on Draft Guidance on Clinical Investigations of Medicinal Products Used in Osteoarthritis | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 15, 2010, 12:00 pm
  126. Drug Regulators, EMEA, Publish Addendum to the Note for Guidance on Evaluation of Medicinal Products Indicated for the Treatment of Bacterial Infections | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 16, 2010, 12:07 pm
  127. Drug Regulators, FDA, Publish Guidance For Industry on Content of a Complete Submission for the Evaluation of Proprietary Names. | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 17, 2010, 12:08 pm
  128. regulators EMEA (EMA), Publish a Concept Paper on the Need For Guidance on Clinical Investigations of Medicinal Products in the Treatment of Diabetes Mellitus | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 25, 2010, 11:33 am
  129. Drug Regulators, EMA (EMEA), Publish draft guidance on Clinical Investigations in the Treatment of Diabetes Mellitus | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 26, 2010, 11:41 am
  130. Drug Regulators, MHRA, Publish Consultation Document on ARM 65 Algopain-EZE 140MG Medicated Plaster, Request to Reclassify a Prodcut from POM to P | Drug Development Consultant and Regulatory Consultant pingbacked Posted February 27, 2010, 11:43 am
  131. Drug Regulators, EMEA (EMA), Publish Draft Guidance on the Investigation of Bioequivalence. | Drug Development Consultant and Regulatory Consultant pingbacked Posted March 1, 2010, 11:49 am
  132. Drug Regulators, FDA, Publish Draft Guidance for Industry, Non-Inferiority Clinical Trials | Drug Development Consultant and Regulatory Consultant pingbacked Posted March 2, 2010, 11:14 am
  133. Drug Regulators, FDA, Publish Draft Guidance on Adaptive Design Clinical Trials for Drugs and Biologicals. | Drug Development Consultant and Regulatory Consultant pingbacked Posted March 4, 2010, 11:23 am
  134. Device Regulators, MHRA, Publish Draft for Comment on Vigilance Systems for CE-Marked Medical Devices - Cardiac Ablation Catheters. | Drug Development Consultant and Regulatory Consultant pingbacked Posted March 6, 2010, 12:30 pm